Recombinant Human IL-2 (CD122-Directed) Protein, CF New

Recombinant Human IL-2 (CD122-Directed) Protein, CF Summary

Il-2 receptor engagement can impact the growth and phenotype of cultured immune cells such as T, NK, or Tumor Infiltrating T cells. By engaging the beta receptor (CD122) with higher affinity, continued proliferation of T cells has been observed. Utilizing generative AI to develop an optimized IL-2 cytokine with enhanced beta receptor (CD122) engagement offers superior performance while maintaining greater than 95% homology to its wild-type counterpart including:

• Enhanced CD122 Binding: Increased affinity to the IL-2 beta receptor (CD122) with decreased affinity to IL-2 alpha receptor (CD25), allowing proliferation of effector T cells
•  allowing proliferation of effector T cells
• Improved Output: Maintains growth of CD8⁺/CD4⁺ T cells for workflows aimed at extending proliferation of T cells.
• Sustained Phenotype: Improved proliferation capacity without increased exhaustion nor more terminally differentiated T cells.

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: IL-2

CD122 directed IL-2 has a 7-fold increased binding affinity to the human IL-2 beta receptor while exhibiting significantly reduced affinity for the IL-2 alpha receptor. According to research by Levin (2012), this configuration results in more effective expansion of effector cells and less Treg (1). Our findings show that CD122 directed IL-2 improves immune cell expansion for workflows requiring significant amounts of IL-2. One concern with improving T cell expansion is the possibility of increasing the number of terminally differentiated and exhausted T cells with reduced anti-tumor activity. However, our studies have shown that CD122 directed IL-2 significantly improves T cell expansion without changing T cell phenotype or the expression of exhaustion markers.

Related Research Areas

• Cancer Biomarkers
• Common gamma Chain Receptor Family
• Conventional/Classical Dendritic Cells
• Cytokines and Receptors in Allergy and Asthma
• Cytokines and Receptors in Tfh Cell Differentiation and Function
• gamma delta T Cells
• Group 1 ILCs
• Infectious Diseases
• Inflammatory Mediators
• Isolation, Culture, and Identification of Natural Killer Cells
• Multiple Sclerosis and Myelin Related Molecules
• NCR+ILC3
• Neuroinflammatory Factors
• Preeclampsia
• Regulatory T Cells (Tregs)
• Search Cytokine and Growth Factor Products
• T Cell Cytokine Signaling
• Th1 Cells
• Th2 Cells
• Th9 Cells